News & Events

ABT-263 and Neurodegeneration

A team at Toronto’s Hospital for Sick Children demonstrated that pharmacological ablation of senescent cells using Navitoclax (ABT-263, Focus Cat#10-3141) caused a rapid increase in neural

READ MORE

REV-ERB agonists and Cancer

Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone

READ MORE

A potential new role for RIP1 kinase

Researchers have discovered that inhibition of RIP1 kinase blocks the progression of multiple sclerosis in an immune-induced demyelination mouse model (EAE) but not a chemically-induced one

READ MORE

20% OFF

For Postdoc
Customers!